149 related articles for article (PubMed ID: 35716210)
1. Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy.
Azevedo-Silva J; Tavares-Valente D; Almeida A; Queirós O; Baltazar F; Ko YH; Pedersen PL; Preto A; Casal M
Med Oncol; 2022 Jun; 39(9):121. PubMed ID: 35716210
[TBL] [Abstract][Full Text] [Related]
2. 3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells.
Chiasserini D; Davidescu M; Orvietani PL; Susta F; Macchioni L; Petricciuolo M; Castigli E; Roberti R; Binaglia L; Corazzi L
J Proteomics; 2017 Jan; 152():329-338. PubMed ID: 27890797
[TBL] [Abstract][Full Text] [Related]
3. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.
Ko YH; Niedźwiecka K; Casal M; Pedersen PL; Ułaszewski S
Yeast; 2019 Apr; 36(4):211-221. PubMed ID: 30462852
[TBL] [Abstract][Full Text] [Related]
4. Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.
El Sayed SM; Mohamed WG; Seddik MA; Ahmed AS; Mahmoud AG; Amer WH; Helmy Nabo MM; Hamed AR; Ahmed NS; Abd-Allah AA
Chin J Cancer; 2014 Jul; 33(7):356-64. PubMed ID: 24636230
[TBL] [Abstract][Full Text] [Related]
5. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.
Ko YH; Verhoeven HA; Lee MJ; Corbin DJ; Vogl TJ; Pedersen PL
J Bioenerg Biomembr; 2012 Feb; 44(1):163-70. PubMed ID: 22328020
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer.
Sun Y; Liu Z; Zou X; Lan Y; Sun X; Wang X; Zhao S; Jiang C; Liu H
J Bioenerg Biomembr; 2015 Aug; 47(4):319-29. PubMed ID: 26054380
[TBL] [Abstract][Full Text] [Related]
7. The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view.
El Sayed SM; Baghdadi H; Zolaly M; Almaramhy HH; Ayat M; Donki JG
Med Hypotheses; 2017 Mar; 100():67-77. PubMed ID: 28236852
[TBL] [Abstract][Full Text] [Related]
8. Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis.
Darabedian N; Chen TC; Molina H; Pratt MR; Schönthal AH
ACS Chem Biol; 2018 Nov; 13(11):3054-3058. PubMed ID: 30395437
[TBL] [Abstract][Full Text] [Related]
9. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.
Pedersen PL
J Bioenerg Biomembr; 2012 Feb; 44(1):1-6. PubMed ID: 22382780
[TBL] [Abstract][Full Text] [Related]
10. MCT1, MCT4 and CD147 expression and 3-bromopyruvate toxicity in colorectal cancer cells are modulated by the extracellular conditions.
Pereira-Vieira J; Azevedo-Silva J; Preto A; Casal M; Queirós O
Biol Chem; 2019 May; 400(6):787-799. PubMed ID: 30699066
[TBL] [Abstract][Full Text] [Related]
11. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.
El Sayed SM; El-Magd RM; Shishido Y; Chung SP; Diem TH; Sakai T; Watanabe H; Kagami S; Fukui K
J Bioenerg Biomembr; 2012 Feb; 44(1):61-79. PubMed ID: 22318356
[TBL] [Abstract][Full Text] [Related]
12. The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.
Ho N; Morrison J; Silva A; Coomber BL
Biosci Rep; 2016 Jan; 36(1):e00299. PubMed ID: 26740252
[TBL] [Abstract][Full Text] [Related]
13. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.
Azevedo-Silva J; Queirós O; Ribeiro A; Baltazar F; Young KH; Pedersen PL; Preto A; Casal M
Biochem J; 2015 Apr; 467(2):247-58. PubMed ID: 25641640
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells.
Petricciuolo M; Davidescu M; Fettucciari K; Gatticchi L; Brancorsini S; Roberti R; Corazzi L; Macchioni L
Heliyon; 2020 Dec; 6(12):e05741. PubMed ID: 33364504
[TBL] [Abstract][Full Text] [Related]
15. D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects.
El Sayed SM; El-Magd RM; Shishido Y; Yorita K; Chung SP; Tran DH; Sakai T; Watanabe H; Kagami S; Fukui K
J Bioenerg Biomembr; 2012 Oct; 44(5):513-23. PubMed ID: 22802136
[TBL] [Abstract][Full Text] [Related]
16. 3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation.
Skaripa-Koukelli I; Hauton D; Walsby-Tickle J; Thomas E; Owen J; Lakshminarayanan A; Able S; McCullagh J; Carlisle RC; Vallis KA
Cancer Metab; 2021 Oct; 9(1):37. PubMed ID: 34649623
[TBL] [Abstract][Full Text] [Related]
17. The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria.
Macchioni L; Davidescu M; Roberti R; Corazzi L
J Bioenerg Biomembr; 2014 Oct; 46(5):389-94. PubMed ID: 25194986
[TBL] [Abstract][Full Text] [Related]
18. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5.
Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H
Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536
[TBL] [Abstract][Full Text] [Related]
19. Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming.
Paiardini A; Tramonti A; Schirch D; Guiducci G; di Salvo ML; Fiascarelli A; Giorgi A; Maras B; Cutruzzolà F; Contestabile R
Biochim Biophys Acta; 2016 Nov; 1864(11):1506-17. PubMed ID: 27530298
[TBL] [Abstract][Full Text] [Related]
20. 3-Bromopyruvate enhances TRAIL-induced apoptosis in human nasopharyngeal carcinoma cells through CHOP-dependent upregulation of TRAIL-R2.
Can Z; Lele S; Zhirui Z; Qiong P; Yuzhong C; Lingling L; Surong Z; Yiming S; Pei Z; Chenchen J; Liu H
Anticancer Drugs; 2017 Aug; 28(7):739-749. PubMed ID: 28471808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
